Literature DB >> 15585450

Resistance to antimicrobial agents: an update.

Michael J Rybak1.   

Abstract

Decades of overuse and misuse of antibiotics have turned the resistance problem into a crisis. Preventive and corrective measures are urgently needed. This article presents a broad overview of the status of antimicrobial resistance. Resistance in key bacterial pathogens such as enterococci, staphylococci, pneumococci, and gram-negative bacilli; resistance to fluoroquinolones, third-generation cephalosporins, and the carbapenems; and mechanisms of resistance are discussed. The article also reviews the adverse impact of resistance on outcomes for patients with nosocomial infections. Finally, a brief overview of how the medical community can face its moment of truth is presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585450     DOI: 10.1592/phco.24.18.203S.52236

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Inhibition of bacterial undecaprenyl pyrophosphate synthase by small fungal molecules.

Authors:  Junji Inokoshi; Yuichiro Nakamura; Saori Komada; Katsuichiro Komatsu; Hideaki Umeyama; Hiroshi Tomoda
Journal:  J Antibiot (Tokyo)       Date:  2016-04-06       Impact factor: 2.649

Review 2.  Prophylactic Antibiotic Therapy for Preventing Poststroke Infection.

Authors:  Stefan Schwarz
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

3.  Identification of pyruvate kinase in methicillin-resistant Staphylococcus aureus as a novel antimicrobial drug target.

Authors:  Roya Zoraghi; Raymond H See; Peter Axerio-Cilies; Nag S Kumar; Huansheng Gong; Anne Moreau; Michael Hsing; Sukhbir Kaur; Richard D Swayze; Liam Worrall; Emily Amandoron; Tian Lian; Linda Jackson; Jihong Jiang; Lisa Thorson; Christophe Labriere; Leonard Foster; Robert C Brunham; William R McMaster; B Brett Finlay; Natalie C Strynadka; Artem Cherkasov; Robert N Young; Neil E Reiner
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

4.  Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.

Authors:  Celine Vidaillac; Molly E Steed; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

5.  In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Authors:  Céline Vidaillac; Steve N Leonard; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

6.  Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.

Authors:  Priya M Rajendran; David Young; Toby Maurer; Henry Chambers; Francoise Perdreau-Remington; Peter Ro; Hobart Harris
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

7.  Treating critical illness: the importance of first doing no harm.

Authors:  Mervyn Singer; Paul Glynne
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

8.  The prevalence of community-associated methicillin-resistant Staphylococcus aureus among outpatient children in a tertiary hospital: A prospective observational study in Riyadh, Saudi Arabia.

Authors:  F Alaklobi; F Aljobair; A Alrashod; R Alhababi; M Alshamrani; W Alamin; Lyubov Lytvyn; F Alrouki; D Mertz
Journal:  Int J Pediatr Adolesc Med       Date:  2015-10-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.